JP2012107021A5 - - Google Patents

Download PDF

Info

Publication number
JP2012107021A5
JP2012107021A5 JP2012001163A JP2012001163A JP2012107021A5 JP 2012107021 A5 JP2012107021 A5 JP 2012107021A5 JP 2012001163 A JP2012001163 A JP 2012001163A JP 2012001163 A JP2012001163 A JP 2012001163A JP 2012107021 A5 JP2012107021 A5 JP 2012107021A5
Authority
JP
Japan
Prior art keywords
enteric coated
enteric
minutes
steroidal anti
proton pump
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012001163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012107021A (ja
JP5712148B2 (ja
Filing date
Publication date
Priority claimed from US10/325,338 external-priority patent/US20040121004A1/en
Application filed filed Critical
Publication of JP2012107021A publication Critical patent/JP2012107021A/ja
Publication of JP2012107021A5 publication Critical patent/JP2012107021A5/ja
Application granted granted Critical
Publication of JP5712148B2 publication Critical patent/JP5712148B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012001163A 2002-12-20 2012-01-06 プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形 Expired - Lifetime JP5712148B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/325,338 US20040121004A1 (en) 2002-12-20 2002-12-20 Dosage forms containing a PPI, NSAID, and buffer
US10/325,338 2002-12-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004565359A Division JP5620622B2 (ja) 2002-12-20 2003-12-11 プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形

Publications (3)

Publication Number Publication Date
JP2012107021A JP2012107021A (ja) 2012-06-07
JP2012107021A5 true JP2012107021A5 (enExample) 2013-03-21
JP5712148B2 JP5712148B2 (ja) 2015-05-07

Family

ID=32593740

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004565359A Expired - Lifetime JP5620622B2 (ja) 2002-12-20 2003-12-11 プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形
JP2012001163A Expired - Lifetime JP5712148B2 (ja) 2002-12-20 2012-01-06 プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004565359A Expired - Lifetime JP5620622B2 (ja) 2002-12-20 2003-12-11 プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形

Country Status (10)

Country Link
US (2) US20040121004A1 (enExample)
EP (1) EP1594499B1 (enExample)
JP (2) JP5620622B2 (enExample)
AT (1) ATE427747T1 (enExample)
CA (1) CA2506930C (enExample)
DE (1) DE60327103D1 (enExample)
ES (1) ES2325502T3 (enExample)
MX (1) MXPA05006629A (enExample)
PL (1) PL213637B1 (enExample)
WO (1) WO2004060372A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
MXPA06000524A (es) * 2003-07-18 2006-08-11 Santarus Inc Formulacion farmaceutica y metodo para tratar desordenes gastrointestinales provocados por acido.
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
AU2005213472A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1784179A4 (en) * 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP1888045B1 (en) * 2005-05-24 2010-09-08 Flamel Technologies Oral pharmaceutical composition for treating a cox-2 mediated condition
WO2007019153A2 (en) * 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
WO2008011083A2 (en) * 2006-07-18 2008-01-24 Cornell Research Foundation, Inc. Compounds for enhancing arginase activity and methods of use thereof
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP2012531430A (ja) * 2009-06-25 2012-12-10 ポーゼン インコーポレイテッド アスピリン療法を必要とする患者を治療するための方法
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
HUE039878T2 (hu) * 2012-09-25 2019-02-28 Bayer Pharma AG Regorafenib és acetilszalicilsav kombinációja kolorektális rák kezelésére
WO2018159787A1 (ja) * 2017-03-01 2018-09-07 国立大学法人北海道大学 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2022177644A1 (en) * 2021-02-16 2022-08-25 Applied Molecular Transport Inc. Methods for treating spondyloarthropathies and related compositions

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554276A (en) * 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4766117A (en) * 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
JPS62277322A (ja) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4757060A (en) * 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
NZ235877A (en) * 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
ZA911453B (en) * 1990-03-19 1991-11-27 Squibb & Sons Inc Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
CA2140347C (en) * 1992-07-28 2001-03-27 Shigeo Nakanishi Injection and injection kit containing omeprazole and its analogs
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
IT1270216B (it) * 1994-06-14 1997-04-29 Recordati Chem Pharm Metodo di stabilizzazione di composti biologicamente attivi mediante microgranuli ricoperti sospendibili in fluidi alimentari
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5763422A (en) * 1995-01-27 1998-06-09 Board Of Regents, The University Of Texas System Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5859271A (en) * 1996-04-15 1999-01-12 Virginia Commonwealth University Cytoprotective compounds
SE515129C2 (sv) * 1996-07-01 2001-06-11 Astrazeneca Ab Blisterförpackning, apparat och förfarande för tillverkning av en blisterförpackning samt användning av en blisterförpackning
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6160020A (en) * 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6800307B1 (en) * 1997-10-24 2004-10-05 Bernard Matthews Plc Cooked sausage and method for making the same
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
HUP0100065A2 (hu) * 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
EP1067919A1 (en) * 1998-03-28 2001-01-17 THE ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Dfmo and sulindac combination in cancer chemoprevention
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6392525B1 (en) * 1998-12-28 2002-05-21 Matsushita Electric Industrial Co., Ltd. Magnetic element and method of manufacturing the same
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
JP3670575B2 (ja) * 2000-01-12 2005-07-13 Ｔｄｋ株式会社 コイル封入圧粉コアの製造方法およびコイル封入圧粉コア
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
IL159129A0 (en) * 2001-06-01 2004-05-12 Pozen Inc PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
US20030235628A1 (en) * 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US20040101494A1 (en) * 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040131676A1 (en) * 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer

Similar Documents

Publication Publication Date Title
JP2012107021A5 (enExample)
Yan et al. Chiral protein supraparticles for tumor suppression and synergistic immunotherapy: an enabling strategy for bioactive supramolecular chirality construction
JP5620622B2 (ja) プロトンポンプ阻害剤、ｎｓａｉｄ及び緩衝剤を含む剤形
JP2012255026A5 (enExample)
WO2007078874A3 (en) Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
JP2019508440A5 (enExample)
JP2018522858A5 (enExample)
JP2010031044A5 (enExample)
JP2014139226A5 (enExample)
JP2008505054A5 (enExample)
JP2018514523A5 (enExample)
JP2017505285A5 (enExample)
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
CY1117556T1 (el) Καψακιο για την προληψη των καρδιαγγειακων νοσων
JP2010534236A5 (enExample)
JP2010013438A5 (ja) 過剰増殖性疾患を治療するための新規な組成物
CY1120240T1 (el) Απο του στοματος χορηγουμενο παρασκευασμα δισκιου ενωσης τετρακυκλινης
JP2014218523A5 (enExample)
JP2015522658A5 (enExample)
JP2015522659A5 (enExample)
JP2016520556A5 (enExample)
UY29192A1 (es) Nuevas formulaciones de comprimidos de liberación modificada para inhibidores de bomba de protón
JP2005145894A (ja) 固形製剤
JP2013522350A5 (enExample)
JP2016013980A5 (enExample)